Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Given Consensus Recommendation of “Hold” by Analysts

Shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) have been assigned an average rating of “Hold” from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold rating and one has issued a buy rating on the company.

Several analysts have recently commented on the company. Redburn Atlantic lowered Bayer Aktiengesellschaft from an “overweight” rating to a “neutral” rating in a report on Monday, September 25th. Wolfe Research started coverage on shares of Bayer Aktiengesellschaft in a report on Wednesday, July 19th. They set an “outperform” rating on the stock. Deutsche Bank Aktiengesellschaft lowered Bayer Aktiengesellschaft from a “buy” rating to a “hold” rating in a report on Tuesday. HSBC raised Bayer Aktiengesellschaft from a “reduce” rating to a “hold” rating in a report on Tuesday, October 10th. They noted that the move was a valuation call. Finally, Berenberg Bank cut shares of Bayer Aktiengesellschaft from a “buy” rating to a “hold” rating in a research note on Wednesday, August 16th.

Bayer Aktiengesellschaft Stock Up 1.0 %

Shares of BAYRY opened at $11.16 on Thursday. Bayer Aktiengesellschaft has a 12-month low of $10.53 and a 12-month high of $17.00. The firm has a fifty day moving average price of $11.75 and a 200-day moving average price of $13.37. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.20 and a quick ratio of 0.78.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings results on Wednesday, November 8th. The company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.10). Bayer Aktiengesellschaft had a negative net margin of 7.98% and a positive return on equity of 14.76%. The firm had revenue of $11.26 billion during the quarter, compared to analysts’ expectations of $12.62 billion. On average, equities analysts expect that Bayer Aktiengesellschaft will post 1.69 EPS for the current year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy.